Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MeVis Medical Solutions AG (M3V.DE)
Bremen, BE, DE
MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It also offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; as well as provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. In addition, the company provides three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians; and internet-based special applications in teleradiology. The company was founded in 1997 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Corporation.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.85% | +0.00% | -0.85% | -7.20% | -6.45% | -5.69% | -7.94% | -24.18% | -29.27% | -15.64% | -54.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Software - Application: +13.0%-5.4% Q1'26: -6.8% (vs Q4'24)
-
EPS growth Software - Application: +28.6%-30.7% Q1'26: -74.2% (vs Q4'24)
-
FCF margin FCF growth · Software - Application: +45.3%+28.7% Q1'26: +0.0% (vs Q4'24)
-
EBIT margin Software - Application: +9.4%+20.4% ★ Q1'26: +0.2% (vs Q4'24)
-
ROIC Software - Application: +7.5%+28.0% ★ Q1'26: +0.2% (vs Q4'24)
-
Share dilution Software - Application: +0.0%+0.0% Q1'26: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Software - Application: -1.16×0.00× ★ Q1'26: 0.00× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
16.01M
est: 14.70M (+8.9%)
|
16.12M
est: 12.10M (+33.2%)
|
18.54M
est: 17.40M (+6.6%)
|
16.76M
est: 16.30M (+2.8%)
|
18.07M
est: 16.50M (+9.5%)
|
17.13M
est: 14.00M (+22.4%)
|
16.21M
est: 13.00M (+24.7%)
|
| EBITDA |
6.77M
est: 4.85M (+39.5%)
|
6.31M
est: 3.99M (+58.2%)
|
7.85M
est: 5.74M (+36.8%)
|
8.03M
est: 7.13M (+12.6%)
|
8.41M
est: 5.44M (+54.5%)
|
5.97M
est: 4.62M (+29.3%)
|
4.77M
est: 4.29M (+11.1%)
|
| EBIT |
5.02M
est: 4.74M (+5.8%)
|
4.56M
est: 3.91M (+16.7%)
|
7.25M
est: 5.62M (+29.0%)
|
7.72M
est: 7.46M (+3.6%)
|
8.17M
est: 5.33M (+53.3%)
|
5.81M
est: 4.52M (+28.5%)
|
4.64M
est: 4.20M (+10.6%)
|
| Net Income |
6.74M
est: 3.35M (+101.1%)
|
4.57M
est: 3.39M (+34.9%)
|
5.62M
est: 5.46M (+3.0%)
|
7.17M
est: 5.27M (+36.2%)
|
8.07M
est: 2.04M (+295.9%)
|
5.70M
est: 3.69M (+54.4%)
|
4.55M
est: 2.66M (+71.1%)
|
| SGA |
820.0K
est: 506.0K (+62.1%)
|
1.99M
est: 416.5K (+378.0%)
|
242.0K
est: 598.9K (-59.6%)
|
157.0K
est: 8.69M (-98.2%)
|
548.0K
est: 567.9K (-3.5%)
|
796.0K
est: 481.9K (+65.2%)
|
773.0K
est: 447.5K (+72.7%)
|
| EPS |
3.76
est: 1.84 (+104.3%)
|
2.51
est: 1.86 (+34.9%)
|
3.09
est: 3.00 (+3.0%)
|
3.94
est: 3.34 (+18.0%)
|
4.43
est: 1.12 (+295.5%)
|
3.13
est: 2.03 (+54.2%)
|
2.50
est: 1.46 (+71.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marcus Kirchhoff | Chairman of the Executive Board & Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for M3V.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
